No Data
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $19
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $18
Express News | HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Positive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy Rating
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Express News | Tenaya Therapeutics Inc - Initial Clinical Data for Ridge-1 Expected in 2025
Ultratech : shouldn't buy tickers that are already up if you're not in it by the time stock drift posts you're too late for the bus most of them fall after pump. most of my runners I'm in weeks earlier long before they run